SUPERNUS PHARMACEUTICALS, INC. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Supernus Pharmaceuticals filed Form 8-K on October 26, 2026, disclosing termination of a material definitive agreement under Item 1.02. The filing provides no specific details regarding the counterparty, dollar amounts, effective date, or business rationale for the termination. Without access to the complete 8-K text body, concrete terms cannot be identified.
Why this rating
Termination flagged as material but specifics absent; cannot assess dollar impact relative to $1.7B market cap without detail
Extracted items
- 1.02 agreement termination
- 9.01 exhibits
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.